Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: JMarcus who wrote (2054)	5/23/2003 1:48:24 PM
From: nigel bates	Respond to of 2243

Shamelessly, I put just put my pitch No need for shame from where I'm standing. Bought a few based on the cash position alone - I look at it as a free hit. nig

To: JMarcus who wrote (2054)	5/23/2003 1:58:17 PM
From: JMarcus	Read Replies (1) \| Respond to of 2243

<<The biotech market has lately been more receptive of such models [long time-line, but huge ultimate potential].>> It is very interesting to compare the 2-year charts for GERN and AVGN. finance.yahoo.com GERN, which is much more constricted cash-wise and which also has a long time-line, has recently gone from roughly cash value at $1.42 per share to a high of $7.40 on 4-2-03, and is now showing strength in prices above $5.00. The chart shows GERN diverging from AVGN recently, but it has done so on good news. Anticipation of Avigen's news is starting to get priced into the stock but the full bump won't hit until the press releases (resumption of Coagulin-B trial and IND for the PD vector) are issued. Then maybe it will close the gap with GERN. Marc